Bughda Reyisa, Dimou Paraskevi, D'Souza Reena R, Klampatsa Astero
Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Immunotargets Ther. 2021 Aug 5;10:313-323. doi: 10.2147/ITT.S291767. eCollection 2021.
Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors.
成纤维细胞活化蛋白(FAP)是一种膜蛋白酶,在癌症相关成纤维细胞(CAF)中高度表达。FAP可通过重塑细胞外基质(ECM)来调节肿瘤微环境(TME),其在CAF上的过表达与多种癌症的不良预后相关。TME在一定程度上是嵌合抗原受体(CAR)-T细胞疗法治疗实体瘤疗效有限的原因。用CAR-T细胞靶向FAP是正在研究的克服TME挑战策略之一。本综述描述了FAP在TME中的作用及其作为CAR-T细胞免疫疗法靶点的潜力,总结了迄今为止抗FAP-CAR-T细胞的临床前研究和临床试验,并综述了增强其在实体瘤中细胞毒性效率的可能优化方法。